Mar 13, 2023
Immutep Announces Initiation of Phase II/III Trial for Eftilagimod Alpha plus Paclitaxel in Metastatic Breast Cancer
Feb 06, 2023
Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC
Jan 29, 2023
Immutep Quarterly Activities Report
Jan 03, 2023
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
Dec 22, 2022
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
